Equities research analysts at Citigroup initiated coverage on shares of Hologic (NASDAQ:HOLX) in a report released on Monday, January 6th, Marketbeat Ratings reports. The firm set a “buy” rating and a $60.00 price target on the medical equipment provider’s stock. Citigroup‘s price target points to a potential upside of 11.26% from the stock’s current price.
Several other brokerages have also recently issued reports on HOLX. Morgan Stanley cut Hologic from an “equal weight” rating to an “underweight” rating in a research report on Thursday, January 2nd. Stifel Nicolaus lifted their price objective on shares of Hologic from $48.00 to $52.00 and gave the company a “hold” rating in a research report on Friday, December 13th. TheStreet downgraded shares of Hologic from a “b-” rating to a “c” rating in a report on Wednesday, November 6th. William Blair restated a “buy” rating on shares of Hologic in a research report on Thursday, November 21st. Finally, ValuEngine upgraded shares of Hologic from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and eight have given a buy rating to the company. Hologic currently has a consensus rating of “Hold” and a consensus price target of $55.38.
HOLX traded up $0.18 during midday trading on Monday, hitting $53.93. The stock had a trading volume of 40,961 shares, compared to its average volume of 1,605,262. The company has a market cap of $14.35 billion, a P/E ratio of 22.16, a price-to-earnings-growth ratio of 2.35 and a beta of 0.76. The company has a debt-to-equity ratio of 1.32, a quick ratio of 1.26 and a current ratio of 1.68. Hologic has a 1 year low of $42.61 and a 1 year high of $54.24. The business has a fifty day moving average of $52.43 and a 200 day moving average of $49.79.
In related news, CEO Stephen P. Macmillan sold 194,396 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $45.91, for a total transaction of $8,924,720.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel John M. Griffin sold 19,624 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $52.86, for a total value of $1,037,324.64. The disclosure for this sale can be found here. In the last quarter, insiders have sold 251,453 shares of company stock valued at $11,871,295. Insiders own 0.90% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of HOLX. Nuveen Asset Management LLC raised its holdings in Hologic by 72,308.7% during the second quarter. Nuveen Asset Management LLC now owns 5,304,658 shares of the medical equipment provider’s stock worth $254,730,000 after acquiring an additional 5,297,332 shares in the last quarter. Point72 Asset Management L.P. boosted its position in shares of Hologic by 203.5% in the second quarter. Point72 Asset Management L.P. now owns 1,056,488 shares of the medical equipment provider’s stock worth $50,733,000 after buying an additional 708,361 shares during the period. AQR Capital Management LLC grew its holdings in shares of Hologic by 323.0% during the second quarter. AQR Capital Management LLC now owns 415,932 shares of the medical equipment provider’s stock valued at $19,973,000 after buying an additional 317,614 shares in the last quarter. Parnassus Investments CA raised its position in Hologic by 1.9% during the third quarter. Parnassus Investments CA now owns 15,825,872 shares of the medical equipment provider’s stock valued at $799,048,000 after buying an additional 300,090 shares during the period. Finally, Man Group plc lifted its stake in Hologic by 30.2% in the 3rd quarter. Man Group plc now owns 1,292,169 shares of the medical equipment provider’s stock worth $65,241,000 after acquiring an additional 299,581 shares in the last quarter. 94.06% of the stock is currently owned by hedge funds and other institutional investors.
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Recommended Story: Technical Indicators – What is a Golden Cross?
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.